Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab

Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab

Abstract The checkpoint inhibitor nivolumab is active in patients with metastatic melanoma who have failed ipilimumab. In this phase I/II study, we assessed nivolumab's safety in 92 ipilimumab-refractory patients with unresectable stage III or IV melanoma, including those who experienced grade...

Full description

Saved in:
Bibliographic Details
Main Authors: Jeffrey S. Weber, Geoffrey T. Gibney, Ragini R. Kudchadkar, Bin Yu, Pingyan Cheng, Alberto J. Martinez, Jodie Kroeger, Allison Richards, Lori McCormick, Valerie E. Moberg, Heather Cronin, Xiuhua Zhao, Michael J. Schell, Y. Ann Chen
Format: Artigo
Language:English
Published: 2016
Online Access:https://doi.org/10.1158/2326-6066.cir-15-0193
https://cancerimmunolres.aacrjournals.org/content/canimm/4/4/345.full.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1158/2326-6066.cir-15-0193
https://cancerimmunolres.aacrjournals.org/content/canimm/4/4/345.full.pdf

Similar Items